Biogen CEO Sees Room to Pursue Two Similar Alzheimer's Hopefuls
Comment of the Day

November 14 2018

Commentary by Eoin Treacy

Biogen CEO Sees Room to Pursue Two Similar Alzheimer's Hopefuls

This article by Naomi Kresge for Bloomberg may be of interest to subscribers. Here is a section:

Both compounds target beta amyloid, a protein consistently found in clumps in the brains of people with Alzheimer’s disease. Both are being tested in patients with very early signs of the disease, following a hypothesis that drugs might work best before Alzheimer’s advances. The companies are still talking with regulators about how to proceed, the CEO said.

Vounatsos, like others researching ways to fight the disease, said it may become necessary to combine different treatments, or give one after the other. “Alzheimer’s disease is so complex that a single silver
bullet will not solve the complexity of the disease for all patient types during the continuum of the evolution of the disease,” he said.

Before companies can engineer combinations, they need to find one that works. Biogen won’t disclose when it expects the final-stage study for its potential blockbuster aducanumab to finish, but it enrolled the last patient over the summer. The trial is planned to be about 18 months long.

Eoin Treacy's view

As the number of people living into their dotage increases, the need to contain the cost of healthcare is increasingly urgent. Alzheimer’s is a scourge for any family afflicted by its long slow ebb of critical faculties so any progress is developing a cure or even a partial treatment are to be welcomed. Progress is being made in early diagnosis but so far there is nothing that resembles a cure. Therefore the first company to come up with a solution, however effective, is likely to benefit considerably since doctors currently have nothing they can prescribe.

Click HERE to subscribe to Fuller Treacy Money Back to top